OMNI® Surgical System Shows Long-Term Efficacy in Comprehensive 22-Study Meta-Analysis for Glaucoma Treatment
核心洞察
Meta-analysis of 22 studies demonstrates significant long-term intraocular pressure (搜索) reduction and decreased medication dependence using the OMNI® Surgical System (搜索) for glaucoma (搜索) treatment.
Real-world data from the IRIS® Registry confirms sustained effectiveness of standalone canaloplasty and trabeculotomy procedures over 36 months in primary open-angle glaucoma (搜索) patients.
New analysis from the ROMEO Study reveals OMNI® achieves comparable pressure and medication reductions across mild, moderate, and advanced glaucoma (搜索) cases.
Sight Sciences, Inc. has announced groundbreaking results from multiple clinical studies validating the long-term effectiveness of its OMNI® Surgical System (搜索) in treating glaucoma (搜索). The comprehensive data will be presented at the upcoming 2025 American Glaucoma Society Annual Meeting.
A landmark meta-analysis encompassing 22 studies has demonstrated the OMNI® Surgical System (搜索)'s ability to achieve significant and sustained reductions in intraocular pressure (搜索) (IOP) while decreasing patients' reliance on medications. This extensive review represents the most comprehensive evaluation of the technology to date.
Real-world evidence from the American Academy of Ophthalmology's IRIS® Registry has further substantiated these findings. The 36-month study, which stands as the largest evaluation of standalone canaloplasty and trabeculotomy procedures, showed maintained IOP reductions and decreased medication requirements in patients with primary open-angle glaucoma (搜索).
Clinical Efficacy Across Disease Severity
The ROMEO Study analysis, published in Clinical Ophthalmology, revealed that the OMNI® system delivers consistent benefits regardless of disease severity. The data demonstrated equivalent effectiveness in lowering IOP and reducing medication usage across mild, moderate, and advanced glaucoma (搜索) cases – a crucial finding for clinicians managing patients across the disease spectrum.
Surgical Innovation in Glaucoma Management
The OMNI® Surgical System (搜索) represents a significant advancement in minimally invasive glaucoma (搜索) surgery (MIGS). The technology combines two established procedures – canaloplasty and trabeculotomy – in a single platform, addressing multiple points of resistance in the conventional outflow pathway.
"These comprehensive clinical outcomes validate OMNI's position as a versatile and effective surgical option for glaucoma (搜索) patients," said Paul Badawi, CEO of Sight Sciences. "The sustained benefits observed across different disease stages particularly highlight the technology's potential to transform the treatment paradigm."
Future Implications
The robust clinical evidence supporting the OMNI® Surgical System (搜索) suggests a promising future for glaucoma (搜索) treatment. With demonstrated efficacy across disease severities and sustained long-term outcomes, the technology offers physicians a valuable tool in their surgical armamentarium for managing this sight-threatening condition.